Robert D. Steiner

Robert D. Steiner

Auto-generated profile, based on publicly available information

Robert D. Steiner

Department of Pediatrics, University of Wisconsin School of Medicine and Public Health , Madison, WI

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
PKPriya S. Kishnani
Priya S. Kishnani
RSRobert D. Steiner
Robert D. Steiner
DBDeeksha Bali
Deeksha Bali
KBKenneth I. Berger
Kenneth I. Berger
BBBarry J. Byrne
Barry J. Byrne
MWMichael S. Watson
Michael S. Watson
Disclaimer: ACMG standards and guidelines are designed primarily as an educational resource for physicians and other health care providers to help them provide quality medical genetic services. Adherence to these standards and guidelines does not necessarily ensure a successful medical outcome. These standards and guidelines should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the geneticist should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. It may be prudent, however, to document in the patient’s record the rationale for any significant deviation from these standards and guidelines.

1 July 1998 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
Christopher WassifChristopher Wassif
Christopher Wassif
CMCheryl Maslen
Cheryl Maslen
SKStivelia Kachilele-Linjewile
Stivelia Kachilele-Linjewile
DLDon Lin
Don Lin
LLLeesa M. Linck
Leesa M. Linck
FPForbes D. Porter
Forbes D. Porter

1 February 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
LWL. M. Ward
L. M. Ward
FRFrank Rauch
Frank Rauch
MWM. P. Whyte
M. P. Whyte
JDJ. D'AStous
J. D'AStous
PGP. E. Gates
P. E. Gates
FGF. H. Glorieux
F. H. Glorieux
Context: Information on the use of oral bisphosphonate agents to treat pediatric osteogenesis imperfecta (OI) is limited. Objective: The objective of the investigation was to study the efficacy and safety of daily oral alendronate (ALN) in children with OI. Design and Participants: We conducted a multicenter, double-blind, randomized, placebo-controlled study. One hundred thirty-nine children (aged 4–19 yr) with type I, III, or IV OI were randomized to either placebo (n = 30) or ALN (n = 109) for 2 yr. ALN doses were 5 mg/d in children less than 40 kg and 10 mg/d for those 40 kg and greater. Main Outcome Measures: Spine areal bone mineral density (BMD) z-score, urinary N-telopeptide of collagen type I, extremity fracture incidence, vertebral area, iliac cortical width, bone pain, physical activity, and safety parameters were measured. Results: ALN increased spine areal BMD by 51% vs. a 12% increase with placebo (P < 0.001); the mean spine areal BMD z-score increased significantly from −4.6 to −3.3 (P < 0.001) with ALN, whereas the change in the placebo group (from −4.6 to −4.5) was insignificant. Urinary N-telopeptide of collagen type I decreased by 62% in the ALN-treated group, compared with 32% with placebo (P < 0.001). Long-bone fracture incidence, average midline vertebral height, iliac cortical width, bone pain, and physical activity were similar between groups. The incidences of clinical and laboratory adverse experiences were also similar between the treatment and placebo groups. Conclusions: Oral ALN for 2 yr in pediatric patients with OI significantly decreased bone turnover and increased spine areal BMD but was not associated with improved fracture outcomes.

1 April 2002 in Journal of Genetic Counseling
Verified
Journal Article
Open access
PDF file
RBRobin L. Bennett
Robin L. Bennett
AMArno G. Motulsky
Arno G. Motulsky
ABAlan Bittles
Alan Bittles
LHLouanne Hudgins
Louanne Hudgins
SUStefanie Uhrich
Stefanie Uhrich
DODebra Olson
Debra Olson
The objective of this document is to provide recommendations for genetic counseling and screening for consanguineous couples (related as second cousins or closer) and their offspring with the goals of1. providing preconception reproductive options2. improving pregnancy outcome and identifying reproductive choices3. reducing morbidity and mortality in the 1st years of life, and4. respecting psychosocial and multicultural issues.The recommendations are the opinions of a multicenter working group (the Consanguinity Working Group (CWG)) with expertise in genetic counseling, medical genetics, biochemical genetics, genetic epidemiology, pediatrics, perinatology, and public health genetics, which was convened by the National Society of Genetic Counselors (NSGC). The consensus of the CWG and NSGC reviewers is that beyond a thorough medical family history with follow‐up of significant findings, no additional preconception screening is recommended for consanguineous couples. Consanguineous couples should be offered similar genetic screening as suggested for any couple of their ethnic group. During pregnancy, consanguineous couples should be offered maternal–fetal serum marker screening and high‐resolution fetal ultrasonography. Newborns should be screened for impaired hearing and detection of treatable inborn errors of metabolism. These recommendations should not be construed as dictating an exclusive course of management, nor does use of such recommendations guarantee a particular outcome. The professional judgment of a health care provider, familiar with the facts and circumstances of a specific case, will always supersede these recommendations.

1 October 2013 in The Lancet
Verified
Journal Article
Closed access
NBNick Bishop
Nick Bishop
SASilvano Adami
Silvano Adami
SAS Faisal Ahmed
S Faisal Ahmed
JAJordi Anton
Jordi Anton
PAPaul Arundel
Paul Arundel
RSRobert D Steiner
Robert D Steiner

1 April 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SRSusan W. Robinson
Susan W. Robinson
CMCynthia D. Morris
Cynthia D. Morris
EGElizabeth Goldmuntz
Elizabeth Goldmuntz
MRMark D. Reller
Mark D. Reller
MJMelanie A. Jones
Melanie A. Jones
CMCheryl L. Maslen
Cheryl L. Maslen